Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive Cgrp-targeting Monoclonal Antibodies
LPNEWS

Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive Cgrp-targeting Monoclonal Antibodies

by prnewswire.com posted 2months ago 146 views
NEW HAVEN, Conn., May 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced additional safety and preliminary efficacy results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor...

In this article